SOPRANO: Macitentan in pulmonary hypertension post left ventricular assist device implantation. A prospective multi-center double-blind randomized placebo-controlled parallel group study to assess the efficacy and safety of macitentan in patients with pulmonary hypertension after left ventricular assist device implantation (Protocol AC-055-205)
I
I-Wen Wang, MD, PhD
Primary Investigator
Overview
The purpose of this study is to evaluate the effect of macitentan (study drug) on the function of the heart and on the pressure in the pulmonary arteries after LVAD implantation.
Description
The purpose of this study is to evaluate the effect of macitentan (study drug) on the function of the heart and on the pressure in the pulmonary arteries after LVAD implantation.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
pulmonary hypertension,1510320657
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
Implantation of LVAD within 45 days
Evidence of pulmonary hypertension based on a right heart catheterization
Exclusion Criteria
COPD
Moderate to severe restricted lung disease
Dialysis
Body weight
Additional Information:Implantation of LVAD within 45 days
Evidence of pulmonary hypertension based on a right heart catheterization
Exclusion Criteria
COPD
Moderate to severe restricted lung disease
Dialysis
Body weight
Participants will be compensated for their participation.
Updated on
25 Apr 2024.
Study ID: 1510320657